Both treatments aim to enable patients with DMD who lack full-length dystrophin, to express a truncated yet functional dystrophin protein similar to that found in patients with BMD, effectively shifting the DMD phenotype toward the BMD-like phenotype. The gene discussed is DMD; the disease is Becker muscular dystrophy.